In focus · trending topic

177Lu-PSMA-617

1 stories · following the connections

First U.S. Multi-center Investigational Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance

By Nasdaq OMXFeb 6, 2017, 11:00 AM UTC